Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Harvard University | OTHER |
Not provided
Not provided
Not provided
Not provided
Nonadherence to medications by patients requiring hemodialysis (HD) leads to unfavorable clinical outcomes.Limited data exist on the influence of pharmacists on pharmacoadherence by patients requiring HD. Therefore, we assessed the impact of patient-centered pharmacist care through the implementation of concepts of Medication Therapy Management (MTM) and motivational interview (MI) on pharmacoadherence and its outcomes in patients requiring HD.
Patients were assessed at baseline for baseline characteristics, dialysis-related factors, and medications records
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eligible participants | Experimental | The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patient-Centered Pharmacist Care | Other | A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in pharmacoadherence of patients requiring HD using electronic medication refill from baseline | Comparing changes in self-reporting of number of medications with electronic prescribing during each of the six interviews | Monthly and up to 6 months |
| Changes in pharmacoadherence of patients requiring HD through the control of serum phosphate level (mmol/L) from baseline | Changes in surrogate laboratory pre-HD serum phosphate level (mmol/L) from baseline | Monthly and up to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Systolic blood pressure (SBP) control in mmHg from baseline as a independent surrogate marker for administration of medications | Changes in Systolic blood pressure (SBP) control in mmHg from baseline and on a monthly basis | Monthly and up to 6 months |
| Changes in serum low-density lipoprotein (LDL) levels in mmol/L from baseline as an independent surrogate marker for the administration of medications |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sherine E Ismail, PharmD, MPH | KAIMRC, King Saud bin Abdulaziz University for Health Sciences, Pharmaceutical Care Department, King Khalid Hospital, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia, Harvard T. H. Chan School of Public Health, Boston, MA, USA | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31722680 | Derived | Ismail S, Al-Subhi A, Youssif E, Ahmed M, Almalki A, Seger DL, Seger AC, Cook E. Patient-centered Pharmacist Care in the Hemodialysis Unit: a quasi-experimental interrupted time series study. BMC Nephrol. 2019 Nov 13;20(1):408. doi: 10.1186/s12882-019-1577-6. |
Not provided
Not provided
I plan to share the listed below data regarding my study for public upon request
After publication, I can share all the supporting information
After publication
Not provided
Not provided
| ID | Term |
|---|---|
| D055118 | Medication Adherence |
| ID | Term |
|---|---|
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
Not provided
Not provided
A Quasi-Experimental Interrupted Time Series Study
Not provided
Not provided
Not provided
Not provided
Changes in serum low-density lipoprotein (LDL) levels in mmol/L from baseline and on a monthly basis |
| Monthly and up to 6 months |
| Changes in Number of Medication-related problems (MRPs) from baseline at month 3 and month 5 | Number | At month 3 and month 5 of the study |
| Types of Medication-related problems (MRPs) | Types of Medication-related problems included in the study as identified in literature: improper drug dosing or selection; initiation of medication without indication; adverse drug events; failure to receive drugs; indication without treatment; suggested alternative therapeutic options; and inappropriate monitoring or laboratory tests required | Total study duration: from month 1 to month 6 |
| Number of accepted therapeutic interventions by the pharmacist | Number of Therapeutic interventions suggested by the pharmacists to alter medication regimen suggested by pharmacist based on discussion and approval of prescribing physicians | Monthly and up to 6 months |
| D001519 | Behavior |